Viking Therapeutics Inc. closed its underwritten public offering of 12,650,000 common shares at $5 apiece with gross proceeds of about $63.3 million.
The shares sold included 1,650,000 shares sold pursuant to the full exercise of underwriters' overallotment option to buy additional shares.
Viking plans to use the net proceeds for continued development of its clinical programs and for general research and development, working capital and general corporate purposes.
William Blair & Co. LLC acted as sole book-running manager and Maxim Group LLC and Roth Capital Partners acted as co-managers for the offering. H.C. Wainwright & Co. acted as a financial adviser for the offering.
